Skip to main content
Kolon TissueGene, Inc. logo

Kolon TissueGene, Inc. — Investor Relations & Filings

Ticker · 950160 ISIN · KR8840120008 LEI · 5493000SYYLC88FUL781 KO Manufacturing
Open in API
Filings indexed 288 across all filing types
Latest filing 2021-03-31 Declaration of Voting R…
Country US United States of America
Listing KO 950160

About Kolon TissueGene, Inc.

https://www.tissuegene.com/

Kolon TissueGene, Inc. is a clinical-stage biopharmaceutical company specializing in the development of advanced cell and gene therapies for orthopedic diseases and degenerative disorders. The company's lead product candidate, TG-C, is a first-in-class, allogeneic cell and gene therapy designed to treat knee osteoarthritis. The therapy aims to reduce pain, improve joint function, and slow the progression of the disease. TG-C is currently in late-stage clinical development, undergoing Phase 3 trials.

Recent filings

Filing Released Lang Actions
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an official announcement of the results of a General Meeting of Shareholders (AGM). It details the approval of financial statements, board appointments, and other resolutions passed during the meeting held on 2021-03-31. This fits the definition of a Declaration of Voting Results & Voting Rights Announcement (DVA).
2021-03-31 Korean
[기재정정]사업보고서 (2020.12)
Annual Report Classification · 95% confidence The document is a 'Correction Report' (정정신고) for a previously filed 'Business Report' (사업보고서), which is the Korean equivalent of a 10-K. It explicitly lists the corrections made to the financial statements (specifically the Statement of Changes in Equity) and the auditor's opinion section. Since this document is a formal amendment to the annual report containing substantive financial data and corrections to the original filing, it is classified as a 10-K. FY 2020
2021-03-24 Korean
[기재정정]감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a regulatory filing from Kolon TissueGene titled 'Audit Report Submission' (감사보고서 제출). It provides the audit opinion, key financial data, and specific financial ratios (such as capital impairment and operating loss) as required by regulatory authorities. While it contains financial data, it is a summary announcement of the audit results rather than the full, multi-page audited financial statement document itself. According to the 'Menu vs Meal' rule, this is a formal regulatory notification of the audit report's filing status. FY 2020
2021-03-24 Korean
[기재정정]사업보고서 (2020.12)
Annual Report Classification · 100% confidence The document is a 'Correction Report' (정정신고) for an Annual Report (사업보고서) filed by Kolon TissueGene. It explicitly lists corrections made to the financial statements (specifically the Statement of Changes in Equity) and the Auditor's Opinion section of the previously submitted Annual Report. Since this is a formal amendment to a 10-K equivalent (Annual Report) and contains substantive financial data corrections, it is classified as a 10-K. FY 2020
2021-03-24 Korean
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a formal regulatory filing titled '감사보고서 제출' (Submission of Audit Report) from Kolon TissueGene. It provides a summary of the audit opinion, key financial data, and auditor information. While it contains financial data, it is a short regulatory announcement notifying the market that the audit report has been submitted, rather than the full annual report itself. According to the 'Menu vs Meal' rule, this is classified as a Report Publication Announcement (RPA). FY 2020
2021-03-23 Korean
사업보고서 (2020.12)
Annual Report Classification · 100% confidence The document is a 'Business Report' (사업보고서) for Kolon TissueGene, Inc. for the fiscal year 2020. It contains comprehensive financial statements, management discussion and analysis, board information, and shareholding details. This is a standard annual filing required by the Financial Supervisory Service (FSS) in South Korea, which corresponds to the 10-K equivalent in the US market. It is not an announcement or a summary, but the full report itself. FY 2020
2021-03-23 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.